Ara 290 vs BPC-157
Extensively Studied vs Extensively Studied
synergistic Complementary tissue repair pathways may enhance wound healing.
Molecular Data
Ara 290 BPC-157
Weight 1,257 Da 1,419.53 Da
Half-life ~20 minutes (SubQ), ~2 minutes (IV) <30 minutes
Chain 11 amino acids 15 amino acids
Type Engineered peptide Pentadecapeptide
Key Benefits
Ara 290
01 Proven tissue protection
02 Nerve regeneration
03 Anti-inflammatory effects
04 Excellent safety profile in clinical trials
BPC-157
01 Accelerated tendon, ligament, muscle, and bone healing
02 Localized tissue repair with direct targeting
03 Superior bioavailability
04 Anti-inflammatory effects
05 Angiogenesis promotion
06 Gastric and intestinal protection
Dosing Protocols
Ara 290
4 mg daily / Once daily
Neuropathy Treatment 4 mg daily Once daily
Tissue Protection 1-8 mg daily Once daily
Acute Intervention 2 mg 3x weekly
BPC-157
250-500mcg / Once or twice daily
Tendon/Joint healing 250-500 mcg 1-2x daily
Serious injury 500-1000 mcg 2x daily
General healing 250-500 mcg 1-2x daily
Maintenance 250 mcg 1x daily
Side Effects
Ara 290
Excellent safety profile in clinical trials with no serious drug-related adverse events
BPC-157
Mild injection site redness
Injection site irritation
Possible mild digestive adjustment (oral)
Contraindications
Recent anti-TNF therapy (within 6 months)
EPO use (within 2 months)
Pregnancy
BMI > 34 kg/m²
Active cancer (due to angiogenic effects)
Pregnancy or breastfeeding
Blood thinners (consult doctor due to angiogenesis)
WADA prohibited for competitive athletes
Research Evidence
Ara 290 BPC-157
Status Extensively Studied Extensively Studied
References 5 studies 6 studies
Latest — January 2025
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.